Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/83770
Webinars Genetic Engineering & Biotechnology News presents an Educational and Informative Audio Webinar A Rapid, Flexible Alternative to ELISA for Protein Detection, Characterization, and Quantitation Register Now! www.genengnews.com/alphatech Tuesday, September 25, 2012 11:00 am ET, 8:00 am PT REGISTRATION IS FREE Recombinant monoclonal antibodies continue to increase as biotherapeutic drug candidates in pharma company pipelines and as reagents for research and diagnostic applications. This growth has created demand for rapid, flexible analytical tools for mAb characterization and quantitation. As more and more biosimilar antibodies enter development, their mandated approval pathway requires extensive analytical, physicochemical, and biological characterization data to demonstrate a high degree of similarity to the reference product. These requirements will demand less time-consuming analytical methods that offer greater range and convenience than conventional methods such as standards ELISAs. In this webinar, participating scientists will describe several applications of Alpha Technology, a bead-based chemistry that following binding of molecules captured on beads, leads to energy transfer from one bead to another, producing a luminescent/fluorescent signal. These applications include development of a method to detect complementary antibody pairs during the hybridoma screening process. The method allows antibody capture from hybridoma derived cell culture supernatants onto assay beads without antibody tagging. Participants will also describe application of this technology to develop a homogeneous immunoassay platform for bioprocess analytics including host cell protein contaminants, and the use of AlphaLISA® to detect saliva proteins for potential use in biomarker detection. In This Webinar You Will Learn Q How investigators used Alpha Technology-based assays to screen hybridomas for anti-ATF3 antibody-positive clones in less than three hours, then developed an AlphaMatrix to discover complementary ATF-3 antibody pairs Q How a generic AlphaLISA assay can be used to quantitate therapeutic antibodies using anti-human IgG antibodies to sandwich the target Q How bioprocess contaminants such as host cell proteins (CHO, E. coli, NS0, and PER.C6® HCP), Protein A, or albumin can be detected with this assay format Q How AlphaLISA has enabled the detection of biomarkers in the complex matrix of saliva, such as including C-reactive protein (CRP) to detect ischemic heart disease Who Should Attend Q Laboratory managers Q QC/QA scientists Q Protein vaccine developers Q Clinical assay development scientists Produced with support from Q Protein assay developers Q Protein biochemists Q Biotherapeutics developers, including biosimilars development scientists Q Biomarker development scientists REGISTER TODAY at www.genengnews.com/alphatech WEBINAR PANELISTS Michael E. Bembenek, Ph.D. Lead Discovery Scientific Fellow Millennium: The Takeda Oncology Company Francesco Lipari, Ph.D. Senior Scientist, Biotherapeutic Applications, PerkinElmer Life Sciences and Technology Chamindie Punyadeera, Ph.D. Senior Research Fellow, The University of Queensland Diamantina Institute and the Translational Research Institute MODERATOR Tamlyn Oliver Managing Editor, Genetic Engineering & Biotechnology News